✨ Free AI Report
Voyager Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Voyager Therapeutics, Inc.
Company Research

Voyager Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Voyager Therapeutics is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Its pipeline includes programs for Alzheimer's...

Analyst-debate audio for Voyager Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Voyager Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Early-stage gene therapy platform targeting large neurological disease markets with encouraging preclinical data, but clinical...

Read the full analyst-debate transcript →
Industry Biotechnology - Gene Therapy / Neurological Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Voyager Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Voyager Therapeutics, Inc. Overview

Pro stress-test →

Voyager Therapeutics is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Its pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system.

Strategic Profile

Pro stress-test →

The company's TRACER™ AAV capsid discovery platform has been used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Programs are advanced through a mix of wholly owned assets and collaborations with partners including Neurocrine, Novartis, Alexion and Transition Bio, with cash runway into 2028 based on current plans and collaboration reimbursements.

Competitive Landscape

Pro stress-test →

Voyager focuses on neurogenetic medicines for CNS disorders, leveraging gene therapy, antibodies, its TRACER capsid discovery platform, and emerging non-viral and small-molecule approaches. Key competitor areas include other tau-targeting programs (Biogen's BIIB080), gene therapy platforms (Solid Biosciences, REGENXBIO), and small-molecule CNS companies.

Industry Context

Voyager Therapeutics, Inc. operates in Biotechnology - Gene Therapy / Neurological Therapeutics.

Key facts

Headquarters: Lexington, Massachusetts · Revenue: $13.4M · Market cap: $222M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Voyager Therapeutics, Inc..

  • Lead programs VY7523 (anti-tau antibody) and VY1706 (tau-silencing gene therapy) are designed to address Alzheimer's disease with 2026 clinical developments planned.
  • Q3 2025 results showed cash position of $229M with runway into 2028 and collaboration revenue of $13.4M.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026CMO resignation and CEO interim clinical leadership assumption
  • February 2026Multiple investor conference participation including Guggenheim, Oppenheimer, and TD Cowen
  • +1 moreTrack every material event for Voyager Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Voyager Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BIIB080 (tau-targeting therapy)Phase 2 tau-targeting program with data expected mid-2026→Gene therapy platformsCompeting AAV-based gene therapy companies for CNS indications→CNS small-molecule programsTraditional pharma approaches to neurodegenerative diseases→

Compare Voyager Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Voyager Therapeutics, Inc. operates in Biotechnology - Gene Therapy / Neurological Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Gene Therapy / Neurological Therapeutics research →
NEW · MCP server

Ask your AI assistant about Voyager Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Voyager Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Voyager Therapeutics, Inc. do this quarter?”
“Is Voyager Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Voyager Therapeutics, Inc. do?+
Voyager Therapeutics is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Its pipeline includes programs for Alzheimer's...
What is Voyager Therapeutics, Inc.'s Cyborg Score?+
Voyager Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Voyager Therapeutics, Inc.'s main competitors?+
Named competitors include BIIB080 (tau-targeting therapy), Gene therapy platforms, CNS small-molecule programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Voyager Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Voyager Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Voyager Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Neurogene Inc.7MeiraGTx Holdings plc7REGENXBIO Inc.64D Molecular Therapeutics, Inc.6Takara Bio Inc.5Rocket Pharmaceuticals, Inc.